These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 25733953)

  • 41. Imaging treatment effects in depression.
    Höflich A; Baldinger P; Savli M; Lanzenberger R; Kasper S
    Rev Neurosci; 2012; 23(3):227-52. PubMed ID: 22752781
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Neural markers of symptomatic improvement during antidepressant therapy in severe depression: subgenual cingulate and visual cortical responses to sad, but not happy, facial stimuli are correlated with changes in symptom score.
    Keedwell P; Drapier D; Surguladze S; Giampietro V; Brammer M; Phillips M
    J Psychopharmacol; 2009 Sep; 23(7):775-88. PubMed ID: 18635699
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Is This Where We Stand After Decades of Research to Develop More Personalized Treatments for Depression?
    Sanacora G
    JAMA Psychiatry; 2020 Jun; 77(6):E560-E561. PubMed ID: 32074267
    [No Abstract]   [Full Text] [Related]  

  • 44. Electroencephalography-derived biomarkers of antidepressant response.
    Iosifescu DV
    Harv Rev Psychiatry; 2011; 19(3):144-54. PubMed ID: 21631160
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Utility of event-related potentials in predicting antidepressant treatment response: An iSPOT-D report.
    van Dinteren R; Arns M; Kenemans L; Jongsma ML; Kessels RP; Fitzgerald P; Fallahpour K; Debattista C; Gordon E; Williams LM
    Eur Neuropsychopharmacol; 2015 Nov; 25(11):1981-90. PubMed ID: 26282359
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Predictive Neuroimaging Markers of Psychotherapy Response: A Systematic Review.
    Chakrabarty T; Ogrodniczuk J; Hadjipavlou G
    Harv Rev Psychiatry; 2016; 24(6):396-405. PubMed ID: 27824635
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Addressing heterogeneity (and homogeneity) in treatment mechanisms in depression and the potential to develop diagnostic and predictive biomarkers.
    Fu CHY; Fan Y; Davatzikos C
    Neuroimage Clin; 2019; 24():101997. PubMed ID: 31525565
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Moving toward a process-oriented perspective in the personalized treatment of depression.
    Kopf-Beck J; Fietz J
    Eur Arch Psychiatry Clin Neurosci; 2021 Apr; 271(3):413-415. PubMed ID: 33666694
    [No Abstract]   [Full Text] [Related]  

  • 49. Immune targets for therapeutic development in depression: towards precision medicine.
    Drevets WC; Wittenberg GM; Bullmore ET; Manji HK
    Nat Rev Drug Discov; 2022 Mar; 21(3):224-244. PubMed ID: 35039676
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Certainly not the first neuroimaging treatment selection biomarker.
    Henderson T; Tarzwell R
    JAMA Psychiatry; 2014 Feb; 71(2):210-1. PubMed ID: 24500631
    [No Abstract]   [Full Text] [Related]  

  • 51. Biomarker-Guided Tailored Therapy.
    Lydiard J; Nemeroff CB
    Adv Exp Med Biol; 2019; 1192():199-224. PubMed ID: 31705496
    [TBL] [Abstract][Full Text] [Related]  

  • 52. microRNA-124: a putative therapeutic target and biomarker for major depression.
    Dwivedi Y
    Expert Opin Ther Targets; 2017 Jul; 21(7):653-656. PubMed ID: 28490207
    [No Abstract]   [Full Text] [Related]  

  • 53. Personalized medicine in psychiatry: problems and promises.
    Ozomaro U; Wahlestedt C; Nemeroff CB
    BMC Med; 2013 May; 11():132. PubMed ID: 23680237
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Opportunities in precision psychiatry using PET neuroimaging in psychosis.
    Coughlin JM; Horti AG; Pomper MG
    Neurobiol Dis; 2019 Nov; 131():104428. PubMed ID: 30904669
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Multimodal approaches to define network oscillations in depression.
    Smart OL; Tiruvadi VR; Mayberg HS
    Biol Psychiatry; 2015 Jun; 77(12):1061-70. PubMed ID: 25681871
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Precision Psychiatry: Biomarker-Guided Tailored Therapy for Effective Treatment and Prevention in Major Depression.
    Jones C; Nemeroff CB
    Adv Exp Med Biol; 2021; 1305():535-563. PubMed ID: 33834417
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The Canadian Biomarker Integration Network in Depression (CAN-BIND): advances in response prediction.
    Kennedy SH; Downar J; Evans KR; Feilotter H; Lam RW; MacQueen GM; Milev R; Parikh SV; Rotzinger S; Soares C
    Curr Pharm Des; 2012; 18(36):5976-89. PubMed ID: 22681173
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Neuroimaging Advance in Depressive Disorder.
    Peng D; Yao Z
    Adv Exp Med Biol; 2019; 1180():59-83. PubMed ID: 31784957
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Treatment Selection in Depression.
    Cohen ZD; DeRubeis RJ
    Annu Rev Clin Psychol; 2018 May; 14():209-236. PubMed ID: 29494258
    [TBL] [Abstract][Full Text] [Related]  

  • 60. New blood test could personalise depression treatment.
    Wise J
    BMJ; 2016 Jun; 353():i3203. PubMed ID: 27277666
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.